| MorphoSys AG announces approval to begin Phase 1b/2a... |
|
Biotechnology company MorphoSys AG (FSE:MOR) said on Monday that the company has been awarded clearance to begin a Phase 1b/2a human clinical trial in patients with... More »
|
|
Individual.com - Nov. 9, 2009
|
| MorphoSys Receives Regulatory Approval to Start Phase 1b/2a... |
|
(Hugin via COMTEX) -- Germany's Paul-Ehrlich-Institute Approves Clinical Trial in Rheumatoid Arthritis Patients MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX)... More »
|
|
TMC Net - Nov. 9, 2009
|
| MorphoSys Gets Regulatory Approval To Begin Phase 1b/2a... |
|
(RTTNews) - MorphoSys AG (MPHSF.PK: News ) said it has received clearance from Germany's Paul-Ehrlich-Institute as well as a positive opinion from the ethics committees in... More »
|
|
RTTNews.com - Nov. 8, 2009
|
| MorphoSys Receives Regulatory Approval to Start Phase 1b/2a... |
|
Germany's Paul-Ehrlich-Institute Approves Clinical Trial in Rheumatoid Arthritis Patients MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has... More »
|
|
Genetic Engineering News - Nov. 8, 2009
|
| MorphoSys Receives Regulatory Approval to Start Phase 1b/2a... |
|
Germany's Paul-Ehrlich-Institute Approves Clinical Trial in Rheumatoid Arthritis Patients MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has... More »
|
|
Marketwire via Yahoo! - Nov. 8, 2009
|
| MorphoSys announces regulatory approval to Start Phase... |
|
Biotechnology company MorphoSys AG (FSE: MOR)(Xetra:MOR) has received clearance from Germany's Paul-Ehrlich-Institute, as well as a positive opinion from the ethics... More »
|
|
Individual.com - Nov. 9, 2009
|
| MorphoSys Receives Regulatory Approval to Start Phase 1b/2a... |
|
Germany's Paul-Ehrlich-Institute Approves Clinical Trial in Rheumatoid Arthritis Patients MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has... More »
|
|
Interest!ALERT - Nov. 9, 2009
|
| MorphoSys Receives Regulatory Approval to Start Phase 1b/2a... |
|
Germany's Paul-Ehrlich-Institute Approves Clinical Trial in Rheumatoid Arthritis Patients MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has... More »
|
|
Stockhouse Canada - Nov. 8, 2009
|
| MorphoSys Receives Regulatory Approval to Start Phase 1b/2a |
|
Germany's Paul-Ehrlich-Institute Approves Clinical Trial in Rheumatoid Arthritis Patients MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has... More »
|
|
Market Wire via MSN Money - Nov. 8, 2009
|
| MorphoSys Receives Regulatory Approval to Start Phase 1b/2a... |
|
Prime Standard Segment, TecDAX) announced today that it has received clearance from Germany's Paul-Ehrlich-Institute as well as a positive opinion from the ethics committees... More »
|
|
Earthtimes.org - Nov. 8, 2009
|